Aqueous Native Subcutaneous Immunotherapy Product
Alleraq Plus is a North American-developed aqueous native subcutaneous immunotherapy (SCIT) product designed for patients with environmental allergies such as dust mites and grass pollens. As a native extract, it offers full allergen potency with the potential for maximal desensitisation under controlled clinical supervision.
Overview
Alleraq Plus is suitable for both single-allergen and multi-allergen therapy, providing flexibility for patients sensitised to one or more allergens. It is administered in clinic following established build-up and maintenance protocols.
Safety Profile
Being a native extract, Alleraq Plus carries a higher risk of local and systemic allergic reactions than allergoid products. Common side effects include:
Common side effects include:
Mild local swelling or redness at the injection site
Temporary itching or discomfort
Rare systemic reactions, managed with standard emergency procedures in the clinic
Effectiveness
Clinical evidence suggests that Alleraq Plus effectively reduces allergic symptoms and medication use.
Symptom improvement typically occurs over several months, with optimal benefit expected over a 3–5 year treatment course.
3–5 year treatment course
Treatment options
Single allergen therapy
Single allergen therapy:
Targeted desensitisation for dust mites or grass pollens.
Multi-allergen therapy
Multi-allergen therapy:
Possible under careful clinical supervision due to higher reaction risk.
Both TGA-registered and non-registered options exist.
Clinics must inform patients that all options are privately funded in Australia, with total treatment costs varying from several hundred to several thousand dollars per year.
Administered via subcutaneous injection in clinic
Initial build-up phase with gradual dose increases
Maintenance phase involves less frequent injections for sustained desensitisation
Requires patient monitoring for potential adverse reactions
Patient Suitability
Alleraq Plus may be appropriate for patients who:
Have confirmed IgE-mediated environmental allergies
Seek maximal potential desensitisation
Can attend regular clinic-based injections
Understand and accept the higher risk profile of native extracts
Australian Context
Not PBS-subsidised; treatment is privately funded
Conclusion
Alleraq Plus provides a high-potency aqueous native SCIT option for patients requiring effective desensitisation to environmental allergens.
Careful clinic-based administration maximises safety while offering the potential for long-term improvement in allergy symptoms.
